Background-We investigated the effects of aging on the responses to endothelin (ET) in conscious old (19.8Ϯ0.6 years) and young adult (6.8Ϯ0.3 years) monkeys and compared these results with those of other vasoconstrictors, eg, phenylephrine (PE) and angiotensin II (Ang II). Methods and Results-The monkeys (Macaca fascicularis) were chronically instrumented. Baseline total peripheral resistance (TPR) was not different between the 2 groups. As expected, TPR rose less (PϽ0.05) with PE (5 g/kg) in old monkeys (34Ϯ3%) than in young monkeys (57Ϯ6%); TPR also rose less with Ang II. Surprisingly, TPR rose more (PϽ0.05) with endothelin-1 (ET-1, 25 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) in old monkeys (36Ϯ6%) than in young monkeys (10Ϯ2%). An ET B receptor agonist, sarafotoxin (S6c, 30 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was administered in the presence of an ET A receptor antagonist, BQ-123 (1 mg/kg). Under these conditions, TPR increased more (PϽ0.05) in old monkeys (59Ϯ10%) than in young monkeys (31Ϯ4%). In the presence of nitric oxide synthase (NOS) inhibition with N W -nitro-L-arginine methyl ester (60 mg/kg), vasoconstriction induced by S6c no longer differed with age, because it was enhanced in young monkeys (PϽ0.05) (68Ϯ9% versus 31Ϯ4%) but not in old monkeys (58Ϯ6% versus 59Ϯ10%). Thus, after NOS inhibition, vasoconstrictor responses to ET were no longer enhanced in old monkeys. Conclusions-Peripheral vasoconstriction (PE and Ang II) is reduced in old monkeys, as expected. Paradoxically, vasoconstriction induced by ET-1 was actually enhanced in old monkeys, which appears to be a result of impaired endothelium-dependent vasodilation, which with ET-1 should involve the ET B receptor. (Circulation. 2001;103:2382-2386.)
I t is generally thought that vascular responses to vasoconstrictors are depressed in older animals [1] [2] [3] [4] [5] [6] and humans. 7, 8 The effects of aging on the vascular responses to endothelin-1 (ET-1), however, are more controversial. 9 -19 Although it would be predicted that ET-1-induced vasoconstriction would also be attenuated with age, it is conceivable that vascular responses to ET-1 are affected differently with age compared with other vasoconstrictors, eg, phenylephrine and angiotensin II (Ang II). Although all these vasoconstrictors may elicit endothelium-mediated vasodilation, ET B receptors are actually located on endothelial cells, which mediate vasodilation through the release of endothelium-derived relaxing factors such as nitric oxide (NO) and prostacyclin. 20 -23 Conversely, ET A receptors, located on smooth muscle cells, mediate vasoconstriction via activation of phospholipase C. 20, 24 ET B receptors are also located on smooth muscle cells, which also elicit vasoconstriction. 25 Although ET B receptormediated vasodilation has been observed in adult healthy humans, 26 the relative contribution of ET B receptors appears to be dependent on vessels and species. 27 More importantly, the effects of aging on each ET receptor subtype have not yet been clarified. A monkey aging model has the advantage of being phylogenetically closer to humans but exhibits fewer of the complicating effects of the diseases associated with aging, eg, diabetes and atherosclerosis. 28 A recent study in this model from our laboratory indicated that with advancing age, vascular responsiveness to endothelium-dependent vasodilation was reduced in the absence of changes in baseline function. 28 Therefore, it would be particularly interesting to determine the effects of ET-1 in this aging monkey model, in which endothelial vasodilation is known to be impaired.
Accordingly, the first goal of the present investigation was to determine whether peripheral vascular responses to vasoconstrictors, eg, phenylephrine and Ang II, and ET-1 are altered in conscious aging monkeys. To address this goal, peripheral vascular responses (total peripheral resistance, TPR) to ET-1 were compared with those to phenylephrine and Ang II. The effects of ET-1, as noted above, are more complex. Therefore, it is conceivable that a change in vasoconstriction with ET-1 could be due to either a change in smooth muscle vasoconstrictor activity or endothelial vasodilator activity. To address this goal, vascular responses to an ET B receptor agonist, sarafotoxin S6c (S6c), were examined in the presence of an ET A receptor antagonist, BQ-123. ET A blockade was administered to allow full expression of ET B activity. Furthermore, to address the question of whether ET B receptor function was NO-dependent, the vascular responses to S6c were also examined in the presence of NO synthase inhibition with N -nitro-L-arginine methyl ester (L-NAME).
Methods

Animals
In the present study, the age of the old monkeys (Macaca fascicularis) averaged 19.8Ϯ0.6 years, and young adult monkeys (6.8Ϯ0.3 years old) were used as controls. The old monkeys were feral animals caught at the age of 5 to 7 years old and were maintained in captivity for 12 to 15 years. The original age was estimated on the basis of an eruption of dentition, general appearance, sexual development, and body weight. The monkeys were tranquilized with ketamine hydrochloride (2 to 3 mg/kg IM), anesthetized with thiamylal sodium (5 to 10 mg/kg IV), and maintained with isoflurane (0.5 to 1.5 vol% in oxygen) for the surgical procedure. Instrumentation was performed as previously described. 28, 29 In brief, an incision was made in the fourth left intercostal space under sterile surgical conditions. Tygon catheters (Norton Elastic and Synthetic Division) were implanted in the descending aorta and left atrium, and a solid-state pressure gauge (Konigsberg Instruments) was inserted into the left ventricle through the apex. A Transonic aortic flow probe (Transonic Systems) was implanted around the root of the ascending aorta to measure ascending aortic flow (cardiac output). The chest incision was closed in layers, and the thorax was evacuated of air. All animals were allowed to recover for 10 to 14 days before experimentation. The animals used in this study were maintained in accordance with guidelines of the Guide for the Care and Use of Laboratory Animals (Department of Health and Human Services publication [National Institutes of Health] No. 83-23, revised 1996).
Hemodynamic measurements were made with the monkeys fully awake, with a tether system to transmit the electronic signals and catheter pressures to the recording electronics. 28, 29 All monkeys were active and eating well in the tether. All hemodynamic measurements were recorded on a digital multiple recorder (PC216Ax, Sony Precision Technology Inc) and on a multiple-channel thermal strip chart (Astro-Med Inc). The fluid-filled catheter in the aorta was connected to a pressure transducer (Datex Ohmeda) for the measurement of arterial pressure. Left ventricular (LV) pressure and a first derivative of LV pressure (dP/dt) were measured with the solidstate pressure gauge. The Transonic flow probe was calibrated in vitro with timed saline collections in a gravity flow system. Zero aortic flow was assumed to occur during mid and late diastole. Cardiac index was calculated as cardiac output divided by body surface area. Body surface area was calculated as 71.84ϫ(body weight) 0.425 ϫ(height) 0.725 . 30 TPR was calculated as the quotient of mean arterial pressure and cardiac index.
Protocol
Bolus injections of phenylephrine (1, 2, 5, and 10 g/kg) and Ang II (0.01, 0.02, and 0.05 g/kg) were administered through the tether via the left atrial catheter, and measurements of phasic and mean arterial pressure, LV pressure, LV dP/dt, and cardiac output were recorded continuously in the conscious monkeys. A steady state for hemodynamic analysis was reached within the first half minute. ET-1 could not be administered in a bolus because a steady state could not be achieved. Accordingly, ET-1 (Peptide Institute Inc) was administered as 3-minute graded infusions of 25, 50, and 100 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 . The selective ET B receptor agonist S6c (Sigma Chemical Co) was administered in the presence of an ET A antagonist, BQ-123 (1 mg/kg), as 5-minute graded infusions of 5, 15, and 30 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 . After 30 to 45 minutes of recovery after S6c infusion, the NO synthase inhibitor L-NAME (60 mg/kg) (Sigma) was administered, and after hemodynamics were stabilized (20 to 30 minutes), S6c infusion was repeated.
Blood Samples
Blood samples were obtained for determination of plasma concentrations of blood urea nitrogen, creatinine, fasting plasma glucose, total cholesterol, and triglycerides by use of the tether system in the morning before feeding. These levels were measured by standard laboratory analyses.
Statistics
All data were reported as meanϮSEM. The comparison between the groups with young and old monkeys was made by unpaired t test for grouped data. The dose-response curves were analyzed by ANOVA for repeated measurements. Values of peak response to each drug administration were compared with baseline by the paired t test. A value of PϽ0.05 was taken as the minimal level of significance.
Results
Characteristics of Body Weight, Height, and Surface Area and Blood Examinations in Young and Old Monkeys
There were no significant differences in body weight, height, and body surface area between the young and old monkeys. Lipid blood levels and plasma fasting glucose were also not different between the young and old monkeys.
Baseline Hemodynamics
There were no significant differences in heart rate (young, 165Ϯ7 versus old, 154Ϯ8 bpm), mean arterial pressure (young, 80Ϯ2 versus old, 79Ϯ3 mm Hg), LV dP/dt (young, 2882Ϯ208 versus old, 3000Ϯ203 mm Hg/s), cardiac index (young, 1.64Ϯ0.06 versus old, 1.59Ϯ0.14 L ⅐ min Ϫ1 ⅐ m Ϫ2 ), and TPR (young, 49Ϯ3 versus old, 51Ϯ3 mm Hg ⅐ L Ϫ1 ⅐ min Ϫ1 ⅐ m Ϫ2 ) between young and old monkeys.
Responses to Phenylephrine, Ang II, and ET-1
Increases in TPR to phenylephrine and Ang II were significantly (PϽ0.05) depressed in old monkeys compared with young monkeys (Figure 1 ). For example, 10 g/kg of phenylephrine increased TPR by 97Ϯ8% in young monkeys versus 47Ϯ6% in old monkeys, and 0.05 g/kg of Ang II increased TPR by 87Ϯ13% in young monkeys versus 57Ϯ3% in old monkeys. The dose relationship of TPR to ET-1, however, was paradoxically reversed (PϽ0.05) in old monkeys compared with young monkeys (Figure 1 ). For example, 25 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 of ET-1 increased TPR less (PϽ0.05) in young monkeys (10Ϯ2%) versus old monkeys (36Ϯ6%).
Response to an ET B Receptor Agonist (S6c) in the Presence of an ET A Receptor Antagonist (BQ-123) Without NO Synthase Inhibition
The ET A receptor antagonist BQ-123 decreased baseline TPR by 10Ϯ3.7% in young monkeys (Pϭ0.05 versus baseline) but did not change TPR in old monkeys (Ϫ0.5Ϯ2.1%, Pϭ0.058 versus young monkeys) ( Figure 2A ). In the presence of the BQ-123, the increases in TPR to the ET B receptor agonist S6c were significantly (PϽ0.05) increased in old monkeys compared with young monkeys (Table, Figure 3A ).
Response to an ET B Receptor Agonist (S6c) in the Presence of ET A Receptor Antagonist (BQ-123) With NO Synthase Inhibition
NO synthase inhibition with L-NAME increased baseline TPR more (PϽ0.05) in young monkeys (126Ϯ6%) than in old monkeys (99Ϯ9%) in the presence of BQ-123 ( Figure  2B ). After L-NAME, there were no differences in the increases in TPR to S6c in old and young monkeys, because S6c increased TPR significantly more in young monkeys compared with the response in the absence of L-NAME ( Figure 3A and 3B) . In old monkeys, in contrast, vasocon-strictor responses to S6c were not enhanced after L-NAME ( Figure 3A and 3B, Table) .
Discussion
The present investigation examined for the first time the effects of vasoconstrictors in general and endothelin in particular in a monkey model of aging that is phylogenetically closer to humans but devoid of complications secondary to associated cardiovascular diseases. The life span of the monkey is thought to be Ϸ25 years. The old monkeys (20 years old) in the present study are thought to be ageequivalent to humans 60 to 70 years old, ie, old but not senescent, and the young monkeys (7 years old) are thought to be age-equivalent to humans 20 to 25 years old, ie, adults, not juveniles.
It is generally thought that peripheral vasoconstrictor responses are depressed in older animals, 1-8 which might also be predicted for ET-1 if this were simply due to changes in smooth muscle tone. The effects of aging on the vasoconstrictor responses to ET-1, however, are more controversial. Depressed vascular responses to ET-1, 9 -14,19,31 no change, 14 -16,32 or increased responses 9, [17] [18] [19] 32 have been demonstrated. In part, these differences can be attributed to responses in different vascular beds 27 or to differences among species. 27 Some of the effects may also be attributed to the denominator, ie, the age of the young animal. Importantly, the controls (young animals) in the present study were 7-year-old adults, ie, not juveniles. In many previous studies, juveniles were actually used as the young animals. 9, [17] [18] [19] Clearly, there can be differences between juveniles and adults as well as differences between adults and aged animals. These potential differences only reconcile some of the previous results. Accordingly, the underlying hypothesis of this investigation was that some of these differences could be attributed to the effects of aging on endothelial vascular control. 33 Because ET-1 exerts different effects on endothelium versus smooth muscle, it follows that the resultant effects of ET-1 administration in older subjects would be affected differentially to the extent that aging impaired endothelial versus smooth muscle control. This is particularly important for this investigation, because we have recently demonstrated impaired endothelial vasodilation in this model of aging. 28 The present results demonstrate depressed peripheral vasoconstriction to activation of ␣ 1 -adrenergic receptors and Ang II receptors. Surprisingly, vasoconstrictor responses to ET-1 were enhanced in the old monkeys. Importantly, baseline hemodynamics in the old monkeys were not different from those in young monkeys.
The next question addressed was the mechanism for the paradoxical responses of ET-1-mediated vasoconstriction in the old monkeys, which has not yet been elucidated. The responses to ET-1 are mediated by at least 2 receptor subtypes, the ET A and ET B receptors. Stimulation of ET A receptors located on smooth muscle cells mediates vasoconstriction via activation of phospholipase C. 20, 24 In addition, vasoconstriction is also mediated by the ET B receptor, which is located in smooth muscle. 25 Conversely, ET B receptors located on endothelium mediate vasodilation through the release of endothelium-derived relaxing factors, such as NO and prostacyclin. 20 -23 ET-1 is generally regarded as a potent vasoconstrictor, but the vascular response to ET-1 must be based on a balance of vasoconstrictor and vasodilator influences. Thus, enhanced vasoconstrictor responses to ET-1 in old monkeys could be due to enhanced vasoconstriction mediated by either ET A receptors or ET B receptors, which are located on smooth muscle cells, or to depressed vasodilation mediated by endothelial ET B receptors. Because peripheral endothelial dysfunction was observed in old monkeys, 28 we hypothesized that the paradoxically enhanced vasoconstrictor response to ET-1 in old monkeys was related to dysfunction of ET B receptors located on endothelium. To test this hypothesis, we examined the effects of an ET B receptor agonist in the presence of ET A receptor blockade. ET A blockade was used to allow full expression of ET B effects.
The ET B agonist S6c increased TPR more in old monkeys than in young monkeys. In the presence of NO inhibition with L-NAME, however, vasoconstriction induced by S6c was enhanced in young monkeys but did not change in old monkeys, resulting in abolition of the differential response of endothelin-induced vasoconstriction in old and young monkeys. These findings suggest that ET B receptor-derived NO production was impaired in old monkeys. This is consistent with the concept of impaired NO-mediated endothelin-dependent vasodilator activity, which has been observed in old monkeys. 28 Responses to an NO donor, sodium nitroprusside, were intact, however, indicating that responses to NO are not impaired.
Because vasoconstrictor responses mediated by the ET B receptor were not enhanced with aging, as evidenced by the data demonstrating similarities between young and old monkeys when the NO synthase pathway was inhibited with L-NAME, depressed endothelial ET B receptor function rather than enhanced smooth muscle ET B receptor function explains the findings in this investigation.
In addition, the ET A receptor antagonist BQ-123 decreased TPR in young monkeys (Pϭ0.05) but did not change TPR in old monkeys. Therefore, it is likely that ET A receptor function is depressed in old monkeys rather than enhanced ( Figure  2A) . This also suggests a greater role for endothelin in regulating peripheral resistance in young monkeys. We did not measure blood endothelin levels in these animals. It has been demonstrated, however, that plasma ET-1 level increases with age, 14 which may induce desensitization and could result in a more important role for endothelin in regulating peripheral resistance in young monkeys.
Seo and Lüscher 19 investigated the effects of aging on ET receptor subtypes in normotensive rats and hypertensive rats. In isolated renal arteries from normotensive rats, they demonstrated that the sensitivity to ET-1 was lower in old rats than in adult rats (but the maximal response to ET-1 was enhanced in old rats), and ET B receptor stimulation induced little vasoconstriction in both adult and old rats. Furthermore, they showed that the release of NO by endothelial ET B receptor stimulation increases with age. This difference from our results may be due to differences in species and vessels studied, 27 to the methods (in vivo versus in vitro), or, as noted above, to differences in the age of the controls ("young" animals), where previous studies compared juveniles with aged animals. 9, [17] [18] [19] Recently, an important role of ET B receptors in the pathogenesis of cardiovascular disease has been suggested. 34 -37 Although it is still controversial whether selective ET A receptor antagonists or nonselective ET A /ET B receptor antagonists are more effective as vasodilators, beneficial vasodilator effects of nonselective ET A /ET B receptor antagonists have been demonstrated in patients with essential hypertension compared with the effect of selective ET A receptor antagonist. 38 Conversely, in healthy subjects, the vasodilator effects of selective ET A receptor antagonists seem to be greater than those of nonselective antagonists. 26 This discrepancy may be, in part, due to impaired ET B receptor-mediated vasodilation in relation to endothelial dysfunction in essential hypertension but not in healthy subjects, which is consistent with the concept put forth in the present investigation. Furthermore, important roles of the ET B receptor subtype in patients with LV systolic dysfunction, 34 in the progression of atherosclerosis, 35 and in the pathogenesis of neointima formation 36, 37 have been demonstrated. Aging, in relation to enhanced responses to ET B receptor-mediated vasoconstriction, may complicate the role of endothelin in these pathological conditions. In summary, paradoxically enhanced vascular responses to ET-1 have been demonstrated in old monkeys without associated cardiovascular diseases compared with young monkeys. The enhanced responses could be explained by impaired endothelial vasodilator function mediated by ET B receptors, which may be a more important mechanism to explain the enhanced vasoconstriction to ET-1 in old monkeys than depressed smooth muscle vasoconstrictor activity with aging. These findings should be considered when ET receptor agonists and antagonists are administered to older patients with cardiovascular disease.
